NOXXON announces leading international pharma to evaluate NOX-A12 in new indication
(WorldNews Netherlands)

NOXXON ANNOUNCES LEADING INTERNATIONAL PHARMA TO EVALUATE NOX-A12 IN NEW INDICATION Berlin, Germany, June 24, 2019, 08.00 a.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that a leading international pharmaceutical company amongst the top-10pharmaceutical companies by worldwide revenue1 has signed an agreement with NOXXON for the purpose of evaluating NOX-A12in a new indication, which will remain undisclosed for competitive reasons. "This agreement is an exceptional opportunity for NOXXON and a chance for NOX-A12 to deliver a broader therapeutic...